Evidence map›Paper›PMID 35701472›Full record

ArticleScientific reports2022

Altered cytoskeletal status in the transition from proneural to mesenchymal glioblastoma subtypes.

Maureen Keller, Magdalena Blom, Lei Liu Conze, Min Guo, Daniel Hägerstrand, Pontus Aspenström

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maureen KellerDepartment of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory, Uppsala University, 751 85, Uppsala, Sweden.
Magdalena BlomDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Lei Liu ConzeDepartment of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory, Uppsala University, 751 85, Uppsala, Sweden.
Min GuoDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Daniel HägerstrandDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Pontus AspenströmDepartment of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory, Uppsala University, 751 85, Uppsala, Sweden. pontus.aspenstrom@igp.uu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is a highly aggressive brain tumor with poor patient prognosis. Treatment outcomes remain limited, partly due to intratumoral heterogeneity and the invasive nature of the tumors. Glioblastoma cells invade and spread into the surrounding brain tissue, and even between hemispheres, thus hampering complete surgical resection. This invasive motility can arise through altered properties of the cytoskeleton. We hypothesize that cytoskeletal organization and dynamics can provide important clues to the different malignant states of glioblastoma. In this study, we investigated cytoskeletal organization in glioblastoma cells with different subtype expression profiles, and cytoskeletal dynamics upon subtype transitions. Analysis of the morphological, migratory, and invasive properties of glioblastoma cells identified cytoskeletal components as phenotypic markers that can serve as diagnostic or prognostic tools. We also show that the cytoskeletal function and malignant properties of glioblastoma cells shift during subtype transitions induced by altered expression of the neurodevelopmental transcription factor SOX2. The potential of SOX2 re-expression to reverse the mesenchymal subtype into a more proneural subtype might open up strategies for novel glioblastoma treatments.

Indexed as

Brain NeoplasmsGlioblastomaCytoskeletonGene Expression Regulation, NeoplasticHumansPrognosis

Identifiers

PMID35701472
PMCPMC9197936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.